• metastatic/advanced - colorectal cancer (mCRC) 2
• mCRC - (neo)adjuvant (NA)
• mCRC - 1st line (L1) 5
• mCRC - 2nd line (L2) 6
• endometrial cancer 10

 

• chemotherapy
• non platinum-based chemotherapy
• nucleoside analogues (pyrimidine/purine)
• capecitabine
• immune chekpoint inhibitors
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab alone
• atezolizumab plus bevacizumab
• atezolizumab plus cometinib
• avelumab based treatment
• avelumab alone
• Immune checkpoint association
• durvalumab plus tremelimumab
• nivolumab plus ipilimumab

• versus all
• vs chemotherapy
• vs non platinum-based chemotherapy
• vs nucleoside analogues (pyrimidine/purine)
• vs capecitabine
• vs Standard of Care (SoC)
• vs non active control
• vs BSC
• vs VEGF(R) inhibitor
• vs bevacizumab based treatment
• vs placebo plus bevacizumab
• vs regorafenib

  All patients

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)   studies

mCRC - 2nd line (L2), ... vs. BSC, meta-analysis of study results

No data for this selection

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;